6 May 2023
Latham & Watkins Advises on 4D Molecular Therapeutics’ Pricing of Upsized Public Offering of Common Stock
Advising firms
Deal team
11 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Phillip Stoup Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Zuzanna Gruca | Latham & Watkins LLP | Associate | corporate | Not stated |
| Raul Gonzalez | Latham & Watkins LLP | Associate | corporate | Not stated |
| Chelsi DeTurk | Latham & Watkins LLP | Associate | corporate | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Chad Jennings | Latham & Watkins LLP | Counsel | regulatory | Washington, D.C. |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Maj Vaseghi | Latham & Watkins LLP | Partner | benefits and compensation | Bay Area |
8 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 120m (US$120.0 million)
- What the figure measures
- Issue size
- Client
- 4D Molecular Therapeutics, Inc.Issuer
- Counterparties
- underwriters (Underwriters)